RATIONALE: Oral Delta-9-tetrahydrocannabinol (Delta(9)-THC; Marinol) is medically available for the treatment of nausea associated with cancer chemotherapy and for wasting syndromes related to HIV/AIDS. Little is known about its reinforcing effects. OBJECTIVE: This study was conducted to characterize the reinforcing effects of oral Delta(9)-THC in experienced marijuana smokers under controlled laboratory conditions. METHODS:Ten healthy male marijuana users completed this 17-day residential study. On days 2, 6, 10, and 14, at 0900 h, participants received a "sample" oral dose of Delta(9)-THC (0, 10, 20 mg) and an alternative reinforcer, a 2 US dollars voucher (redeemable for cash at study's end). Over the next 3 days, they had 11 opportunities to self-administer either the sampled dose of Delta(9)-THC or to receive a 2 US dollars voucher. RESULTS: Participants chose active Delta(9)-THC (10 and 20 mg) more often than placebo (<two selections vs approximately four selections, respectively). However, they chose active Delta(9)-THC on less than 50% of choice opportunities. Both active Delta(9)-THC doses produced significant increases in "positive" subjective effects, impaired psychomotor performance, and increased heart rate, relative to the placebo conditions. CONCLUSION: These data indicate that oral Delta(9)-THC may have modest abuse liability in experienced marijuana smokers.
RCT Entities:
RATIONALE: Oral Delta-9-tetrahydrocannabinol (Delta(9)-THC; Marinol) is medically available for the treatment of nausea associated with cancer chemotherapy and for wasting syndromes related to HIV/AIDS. Little is known about its reinforcing effects. OBJECTIVE: This study was conducted to characterize the reinforcing effects of oral Delta(9)-THC in experienced marijuana smokers under controlled laboratory conditions. METHODS: Ten healthy male marijuana users completed this 17-day residential study. On days 2, 6, 10, and 14, at 0900 h, participants received a "sample" oral dose of Delta(9)-THC (0, 10, 20 mg) and an alternative reinforcer, a 2 US dollars voucher (redeemable for cash at study's end). Over the next 3 days, they had 11 opportunities to self-administer either the sampled dose of Delta(9)-THC or to receive a 2 US dollars voucher. RESULTS:Participants chose active Delta(9)-THC (10 and 20 mg) more often than placebo (<two selections vs approximately four selections, respectively). However, they chose active Delta(9)-THC on less than 50% of choice opportunities. Both active Delta(9)-THC doses produced significant increases in "positive" subjective effects, impaired psychomotor performance, and increased heart rate, relative to the placebo conditions. CONCLUSION: These data indicate that oral Delta(9)-THC may have modest abuse liability in experienced marijuana smokers.
Authors: H Valerie Curran; Catherine Brignell; Sally Fletcher; Paul Middleton; John Henry Journal: Psychopharmacology (Berl) Date: 2002-07-23 Impact factor: 4.530
Authors: Jason M Wiebelhaus; Travis W Grim; Robert A Owens; Matthew F Lazenka; Laura J Sim-Selley; Rehab A Abdullah; Micah J Niphakis; Robert E Vann; Benjamin F Cravatt; Jenny L Wiley; S Stevens Negus; Aron H Lichtman Journal: J Pharmacol Exp Ther Date: 2014-11-14 Impact factor: 4.030
Authors: Mohammed A Issa; Sanjeet Narang; Robert N Jamison; Edward Michna; Robert R Edwards; David M Penetar; Ajay D Wasan Journal: Clin J Pain Date: 2014-06 Impact factor: 3.442